

UW Veterinary Care
UNIVERSITY OF WISCONSIN–MADISON

LOOKING FOR

Dogs with Age-Related Debilitation

Evaluation of a novel drug used to restore some cognitive and biological effects of aging.

The Study

Most dogs, regardless of breed, experience some form of age-related debilitation as they get older. Symptoms of age-related debilitation include confusion, anxiety or restlessness, decreased desire to play, and changes in sleep cycle. We are investigating a novel drug (RPh201) that has been found in preliminary studies to restore some of the cognitive and biological effects of aging. RPh201 is a botanical extract isolated from the mastic tree, which grows primarily in dry and rocky areas in Mediterranean Europe.

The objective of this study is to evaluate the safety and preliminary efficacy of RPh201 for Injection in dogs with age-related debilitation when administered once weekly for 16 weeks. This is a placebo-controlled study in which dogs are randomized to receive either RPh201 or placebo. Given the design of the study, a dog is twice more likely to receive RPh201 than to be given a placebo. At the study end visit (week 17), the treatment code will be broken and if a dog has been receiving placebo, the dog will be eligible to receive 16 weeks of treatment with RPh201 at no cost.

Who Qualifies

Dogs at least eight years old and deemed cognitively or otherwise age-debilitated as defined by the owner's and clinician's assessment may be eligible for this study

What Happens

The study drug (RPh201 or placebo) will be administered by a subcutaneous (just under the skin) injection. The owner will be shown how to administer the study drug at the first treatment and subsequent treatments can be administered by the owner. Dogs will be evaluated at UW Veterinary Care prior to treatment and at week 1, 5, 9, 13, and 17. At each visit, blood and urine samples will be collected for analysis. The pretreatment and week 1, 9, and 17 evaluations will also include consults with ophthalmology, neurology, and orthopedic clinicians. Prior to treatment and at week 17, a small (1/4 inch) skin biopsy will be performed. In addition, an activity monitor (Fitbark®) will be provided for each dog which is to be placed on the dog's collar for 7 days prior to treatment and during week 8 and 16.

Why Participate

All study-related treatments and evaluations will be paid for by the study. In addition, when a dog completes the study, a financial incentive of $500 (five hundred dollars) will be provided as a UW Veterinary Care credit.

More Information

Please contact the Dr Kim at the UW Veterinary Care Oncology Service at 608-263-7600 or email ckim258@wisc.edu

Revised GH 1/9/2018